Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could becom...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Intest Res
Egile Nagusiak: Koga, Akihiro, Matsui, Toshiyuki, Takatsu, Noritaka, Takada, Yasumichi, Kishi, Masahiro, Yano, Yutaka, Beppu, Takahiro, Ono, Yoichiro, Ninomiya, Kazeo, Hirai, Fumihito, Nagahama, Takashi, Hisabe, Takashi, Takaki, Yasuhiro, Yao, Kenshi, Imaeda, Hirotsugu, Andoh, Akira
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Korean Association for the Study of Intestinal Diseases 2018
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5934595/
https://ncbi.nlm.nih.gov/pubmed/29743835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2018.16.2.223
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak